Effects of antihypertensive treatment on systolic blood pressure and renin in experimental hypertension in rats. 1979

J L Cangiano, and C Rodríguez-Sargent, and M Martínez-Maldonado

The effects of pretreatment with hydralazine and alpha-methyldopa were assessed in rats made hypertensive by ligation of the left renal artery (LRA). Systolic blood pressure and peripheral renin activity (PRA) were measured 7 and 1 day before LRA and 2, 7 and 28 days after LRA. Systolic blood pressure increased 2 days after LRA in control and alpha-methyldopa-treated rats but not in the hydralazine-treated rats. Peripheral renin activity levels did not correlate with changes in systolic blood pressure. Peripheral renin activity first increased 7 days after LRA but decreased 28 days after LRA despite persistent hypertension in controls and alpha-methyldopa-treated rats. It is concluded that factors other than renin are involved in the initial and maintenance phases of this experimental model. In addition, hydralazine protects the rat with LRA from developing hypertension.

UI MeSH Term Description Entries
D006977 Hypertension, Renal Persistent high BLOOD PRESSURE due to KIDNEY DISEASES, such as those involving the renal parenchyma, the renal vasculature, or tumors that secrete RENIN. Hypertensions, Renal,Renal Hypertension,Renal Hypertensions
D006978 Hypertension, Renovascular Hypertension due to RENAL ARTERY OBSTRUCTION or compression. Hypertension, Goldblatt,Goldblatt Syndrome,Goldblatt Hypertension,Renovascular Hypertension,Syndrome, Goldblatt
D008026 Ligation Application of a ligature to tie a vessel or strangulate a part. Ligature,Ligations,Ligatures
D008750 Methyldopa An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent. Methyldopate,alpha-Methyldopa,Aldomet,Alphamethyldopa,Apo-Methyldopa,Dopamet,Dopegit,Dopegyt,Dopergit,Hydopa,Meldopa,Nu-Medopa,Sembrina,alpha-Methyl-L-Dopa,Apo Methyldopa,Nu Medopa,alpha Methyl L Dopa,alpha Methyldopa
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D005260 Female Females
D006830 Hydralazine A direct-acting vasodilator that is used as an antihypertensive agent. Hydrallazin,Apresoline,Apressin,Apressoline,Hydralazine Hydrochloride,Hydralazine mono-Hydrochloride,Hydrazinophthalazine,Nepresol,Hydralazine mono Hydrochloride,Hydrochloride, Hydralazine,mono-Hydrochloride, Hydralazine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000959 Antihypertensive Agents Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. Anti-Hypertensive,Anti-Hypertensive Agent,Anti-Hypertensive Drug,Antihypertensive,Antihypertensive Agent,Antihypertensive Drug,Anti-Hypertensive Agents,Anti-Hypertensive Drugs,Anti-Hypertensives,Antihypertensive Drugs,Antihypertensives,Agent, Anti-Hypertensive,Agent, Antihypertensive,Agents, Anti-Hypertensive,Agents, Antihypertensive,Anti Hypertensive,Anti Hypertensive Agent,Anti Hypertensive Agents,Anti Hypertensive Drug,Anti Hypertensive Drugs,Anti Hypertensives,Drug, Anti-Hypertensive,Drug, Antihypertensive,Drugs, Anti-Hypertensive,Drugs, Antihypertensive

Related Publications

J L Cangiano, and C Rodríguez-Sargent, and M Martínez-Maldonado
May 2000, Kidney international,
J L Cangiano, and C Rodríguez-Sargent, and M Martínez-Maldonado
March 1993, Journal of hypertension. Supplement : official journal of the International Society of Hypertension,
J L Cangiano, and C Rodríguez-Sargent, and M Martínez-Maldonado
September 1984, The American journal of medicine,
J L Cangiano, and C Rodríguez-Sargent, and M Martínez-Maldonado
June 1995, Cardiovascular drugs and therapy,
J L Cangiano, and C Rodríguez-Sargent, and M Martínez-Maldonado
March 2019, Annals of family medicine,
J L Cangiano, and C Rodríguez-Sargent, and M Martínez-Maldonado
August 2009, Hypertension (Dallas, Tex. : 1979),
J L Cangiano, and C Rodríguez-Sargent, and M Martínez-Maldonado
September 2007, Archives of internal medicine,
J L Cangiano, and C Rodríguez-Sargent, and M Martínez-Maldonado
October 2005, Statistics in medicine,
J L Cangiano, and C Rodríguez-Sargent, and M Martínez-Maldonado
April 2013, American journal of hypertension,
J L Cangiano, and C Rodríguez-Sargent, and M Martínez-Maldonado
April 2011, Zhonghua xin xue guan bing za zhi,
Copied contents to your clipboard!